Adding targeted therapy drug to standard treatment benefits aggressive breast cancer

[News]

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

More... (https://www.news-medical.net/news/20190929/Adding-targeted-therapy-drug-to-standard-treatment-benefits-aggressive-breast-cancer-patients.aspx)